Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

The British Big Pharma has filed depemokimab for FDA approval in two respiratory indications on the back of new phase 3 data showing the antibody improved disease symptoms and quality of life in ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy ...

Depemokimab’s PDUFA date is set for December 16, 2025, with FDA reviewing two indications. Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Join Nic Chahine ...

In the study, "Efficacy and Safety of Twice-Yearly Depemokimab in Chronic Rhinosinusitis with Nasal Polyps (ANCHOR-1 and ANCHOR-2)," published in The Lancet, researchers conducted randomized ...

A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo. The FDA has accepted GSK’s ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...